Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow on course for slim gains at open as Iran tensions clash with AI optimism
- Oil retreats from one-month high as traders weigh supply risks
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
Needham on Medtronic, Inc. (MDT): 'We believe that MDT is in the early stages of a strong product cycle'
September 1, 2026 1:27 PM EDTNeedham analyst Michael Matson reiterated a Buy rating and $114.00 price target on Medtronic, Inc. (NYSE: MDT).
The analyst comments "MDT's F1Q27 revenue and EPS beat consensus, and management raised FY27 revenue and EPS guidance. Organic growth improved to 7.0%... More
